Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 22NIH 5INDUSTRY 4UNKNOWN 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 26CNS 18Other hematologic neoplasm 15Sarcoma 14Gynecologic 7Genitourinary 5Plasma cell 2Myeloid 2Classical hematology 2Thoracic 1Other solid neoplasm 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Inflammatory Breast Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 42Docetaxel 33Paclitaxel 31Tamoxifen 29Doxorubicin 29Trastuzumab 25Radiotherapy 21Epirubicin 16Letrozole 15Anastrozole 12exemestane 11Fluorouracil 11Capecitabine 10Bevacizumab 10palbociclib 9Immunohistochemistry 9Fulvestrant 9Filgrastim 9Lapatinib 8Zoledronic Acid 7Methotrexate 7Magnetic Resonance Spectroscopy 7Gene Expression Profiling 7pertuzumab 6Triptorelin Pamoate 6Taxes 6Surgical Procedures, Operative 6Microarray Analysis 6Goserelin 6Chemotherapy, Adjuvant 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Granulocyte Colony-Stimulating Factor × Breast × Clear all
NCT00016406 2013-01-24

S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer

SWOG Cancer Research Network

Phase 3 Completed
399 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡